New injection aims to tame tough eczema

NCT ID NCT07693738

Recruiting now Disease control Sponsor: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jul 09, 2026 · Last updated Jul 10, 2026 · Updated 1 time

Summary

This early-stage trial tests an investigational drug called SSGJ-716, given as an injection, to see if it is safe and tolerable. The study first enrolls healthy adults to test a single dose, then moves to people with moderate-to-severe atopic dermatitis (a type of eczema) who receive multiple doses. The goal is to gather initial safety data and understand how the drug moves through the body.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: SSGJ-716 injection
What this could lead to: If safe and effective, SSGJ-716 could become a new treatment option for moderate-to-severe atopic dermatitis, helping control symptoms like itching and rash.
What could go wrong: This is an early Phase 1 trial focused on safety, not yet on effectiveness. The drug may cause side effects or fail to show benefit in later studies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AD are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Alzheimer disease atopic eczema

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AD

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Huashan Hospital, Fudan University
RECRUITING

Shanghai, 200040, China

Contact

More trials for these conditions

Other studies related to the condition(s) this trial covers.